Published in Semin Cancer Biol on February 01, 2003
Ubiquitylation and cell signaling. EMBO J (2005) 4.65
Nbs1 is required for ATR-dependent phosphorylation events. EMBO J (2004) 1.95
Functional relationships of FANCC to homologous recombination, translesion synthesis, and BLM. EMBO J (2004) 1.56
XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol Cell Biol (2009) 1.50
The loop-less tmCdc34 E2 mutant defective in polyubiquitination in vitro and in vivo supports yeast growth in a manner dependent on Ubp14 and Cka2. Cell Div (2011) 1.48
The DNA translocase FANCM/MHF promotes replication traverse of DNA interstrand crosslinks. Mol Cell (2013) 1.32
Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol (2004) 1.32
The Fanconi anemia protein FANCM is controlled by FANCD2 and the ATR/ATM pathways. J Biol Chem (2009) 0.99
CCAAT/enhancer binding protein delta (C/EBPdelta, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage. Proc Natl Acad Sci U S A (2010) 0.94
Haploinsufficiency of DNA Damage Response Genes and their Potential Influence in Human Genomic Disorders. Curr Genomics (2008) 0.91
Fanconi anemia A is a nucleocytoplasmic shuttling molecule required for gonadotropin-releasing hormone (GnRH) transduction of the GnRH receptor. Endocrinology (2006) 0.82
The 'ubiquitous' reality of vector immunology. Cell Microbiol (2013) 0.82
The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways. J Biol Chem (2017) 0.77
Involvement of ALAD-20S Proteasome Complexes in Ubiquitination and Acetylation of Proteasomal α2 Subunits. J Cell Biochem (2016) 0.76
FANCI is a negative regulator of Akt activation. Cell Cycle (2016) 0.75
Biallelic inactivation of BRCA2 in Fanconi anemia. Science (2002) 9.31
Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell (2007) 6.68
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
How the fanconi anemia pathway guards the genome. Annu Rev Genet (2009) 4.94
Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol (2006) 4.67
The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell (2005) 4.40
S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood (2002) 4.27
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med (2003) 4.04
Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A (2005) 3.93
The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev (2005) 3.90
Molecular pathogenesis of Fanconi anemia: recent progress. Blood (2006) 3.76
Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell (2002) 3.71
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol (2010) 3.54
ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev (2004) 3.44
Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev (2012) 3.42
Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev (2010) 3.33
A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol Cell (2007) 3.27
Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol (2004) 3.20
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. Blood (2008) 2.83
Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol (2006) 2.73
Inhibition of homologous recombination by the PCNA-interacting protein PARI. Mol Cell (2011) 2.61
UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell (2006) 2.51
DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol (2006) 2.49
Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst (2006) 2.42
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med (2011) 2.35
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 2.33
Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell (2012) 2.26
The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum Mol Genet (2005) 2.23
Chromatin remodeling at DNA double-strand breaks. Cell (2013) 2.18
UAF1 is a subunit of multiple deubiquitinating enzyme complexes. J Biol Chem (2008) 2.17
Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res (2007) 2.14
Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell (2009) 2.12
Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. Blood (2004) 2.08
A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst (2012) 2.07
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol (2002) 1.96
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther (2006) 1.88
Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest (2007) 1.80
Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest (2012) 1.79
Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res (2003) 1.78
Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol (2007) 1.77
The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly. DNA Repair (Amst) (2008) 1.74
Regulation of Rev1 by the Fanconi anemia core complex. Nat Struct Mol Biol (2012) 1.72
Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol (2006) 1.65
A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood (2002) 1.54
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood (2003) 1.49
DNA polymerase POLN participates in cross-link repair and homologous recombination. Mol Cell Biol (2009) 1.47
Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through Its interactions with PCNA and USP1. J Biol Chem (2010) 1.43
Case records of the Massachusetts General Hospital. Case 13-2006. A 50-year-old man with a painful bone mass and lesions in the liver. N Engl J Med (2006) 1.42
Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. Dev Cell (2003) 1.38
Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells. J Clin Invest (2010) 1.38
The FANCM/FAAP24 complex is required for the DNA interstrand crosslink-induced checkpoint response. Mol Cell (2010) 1.35
Direct DNA binding activity of the Fanconi anemia D2 protein. J Biol Chem (2005) 1.33
MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol Cancer Res (2011) 1.33
DNA damage responses and their many interactions with the replication fork. Carcinogenesis (2006) 1.32
The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Mol Cell Biol (2011) 1.31
Regulation of the Fanconi anemia pathway by a SUMO-like delivery network. Genes Dev (2011) 1.28
Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell (2009) 1.27
Dedicated to the core: understanding the Fanconi anemia complex. DNA Repair (Amst) (2006) 1.27
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med (Berl) (2007) 1.26
Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. Genes Dev (2009) 1.25
The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC. Blood (2002) 1.24
The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair. Exp Cell Res (2006) 1.24
Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2. Cancer Res (2003) 1.23
Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A (2013) 1.22
WDR20 regulates activity of the USP12 x UAF1 deubiquitinating enzyme complex. J Biol Chem (2010) 1.20
Natural gene therapy in monozygotic twins with Fanconi anemia. Blood (2006) 1.20
Chromatin recruitment of DNA repair proteins: lessons from the fanconi anemia and double-strand break repair pathways. Mol Cell (2008) 1.19
Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood (2004) 1.18
The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly. J Biol Chem (2006) 1.17
Fancd2 functions in a double strand break repair pathway that is distinct from non-homologous end joining. Hum Mol Genet (2005) 1.15
Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants. Hum Mol Genet (2002) 1.13
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer (2009) 1.12
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A (2013) 1.11
FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. Mol Cell (2013) 1.11
The Fanconi anemia pathway and ubiquitin. BMC Biochem (2007) 1.10
Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. Mol Cancer Res (2012) 1.08
MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res (2012) 1.07
Structural basis of Rev1-mediated assembly of a quaternary vertebrate translesion polymerase complex consisting of Rev1, heterodimeric polymerase (Pol) ζ, and Pol κ. J Biol Chem (2012) 1.07
RAD18-dependent recruitment of SNM1A to DNA repair complexes by a ubiquitin-binding zinc finger. J Biol Chem (2010) 1.05
Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci (2011) 1.05
Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer (2012) 1.04
Systematic screen identifies miRNAs that target RAD51 and RAD51D to enhance chemosensitivity. Mol Cancer Res (2013) 1.01
Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther (2013) 0.99
A new nuclease member of the FAN club. Nat Struct Mol Biol (2010) 0.98
The interplay of Fanconi anemia proteins in the DNA damage response. DNA Repair (Amst) (2004) 0.98
Inactivation of Uaf1 causes defective homologous recombination and early embryonic lethality in mice. Mol Cell Biol (2013) 0.98
Structural determinants of human FANCF protein that function in the assembly of a DNA damage signaling complex. J Biol Chem (2006) 0.97
Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol (2003) 0.96